Amgen’s KAI Deal Pays Off With Positive Phase III Trial Of Sensipar Successor
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug acquired for $315 million in cash from KAI in 2012 – AMG 416 – hits all primary and secondary endpoints in first pivotal study of hyperparathyroidism in dialysis patients; two other trials have yet to report.
You may also be interested in...
Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity
Medicare’s bundling policy for drugs and services in dialysis has turned on the pricing pressure in kidney disease. The cost containment policies have negatively impacted sales of some drugs and put a spotlight on growing costs in chronic kidney disease and end-stage renal disease. Nonetheless, there is plenty of opportunity for new drugs that can address the area’s unmet medical need, especially if they can help to reduce broader health care spending. That will require demonstrating value to payors and providers, however, particularly for drugs that treat secondary conditions associated with kidney disease.
Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar
Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.